Genetic engineering of bio-nanoparticles for drug delivery: A review

Journal of Biomedical Nanotechnology

Volumn 10, Issue 9, 2014, Pages 2063-2085

  Nishimura, Yuya ^a   Ishii, Jun ^a   Ogino, Chiaki ^a   Kondo, Akihiko ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Drug delivery; Genetic engineering; Inorganic nanoparticles; Nanoparticles; Virus Like particles

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADATION; BIOLOGICAL MATERIALS; DRUG DELIVERY; GENES; GENETIC ENGINEERING; NANOPARTICLES; POLYPEPTIDES;

ADENO-ASSOCIATED VIRUS; BIO-BASED MATERIALS; DRUG DELIVERY SYSTEM; ELASTIN-LIKE POLYPEPTIDES; HUMAN IMMUNODEFICIENCY VIRUS-1; INORGANIC MATERIALS; INORGANIC NANOPARTICLE; VIRUS-LIKE PARTICLES;

VIRUSES;

BIOPOLYMER; ELASTIN LIKE POLYPEPTIDE; NANOPARTICLE; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; DRUG DELIVERY SYSTEM; ENCAPSULATION; GENETIC ENGINEERING; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; NANOTECHNOLOGY; REVIEW; SENDAI VIRUS; SIMIAN VIRUS 40; VIRUS LIKE AGENT; ANIMAL; CHEMISTRY; HUMAN; ULTRASTRUCTURE;

ANIMALS; DRUG DELIVERY SYSTEMS; GENETIC ENGINEERING; HUMANS; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84904908720     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1951     Document Type: Review

References (261)

1. J. A. Salzmann, Effect of molecular genetics and genetic engineering on the practice of orthodontics. Am. J. Orthod. 61, 5 (1972).
2. T. W. Jeffries, Engineering yeasts for xylose metabolism. Curr. Opin. Biotechnol. 17, 3 (2006).
3. J. Ishii, N. Fukuda, T. Tanaka, C. Ogino, and A. Kondo, Protein-protein interactions and selection: Yeast-based approaches that exploit guanine nucleotide-binding protein signaling. FEBS J. 277, 9 (2010).
4. T. Hasunuma, F. Okazaki, N. Okai, K. Y. Hara, J. Ishii, and A. Kondo, A review of enzymes and microbes for lignocellulosic biorefinery and the possibility of their application to consolidated bioprocessing technology. Bioresour. Technol. 135 (2013).
5. J. T. Kittleson, G. C. Wu, and J. C. Anderson, Successes and failures in modular genetic engineering. Curr. Opin. Chem. Biol. 16, 3 (2012).
6. J. F. Spencer, D. M. Spencer, and N. Reynolds, Genetic manipulation of non-conventional yeasts by conventional and non-conventional methods. J. Basic Microbiol. 28, 5 (1988).
7. J. Ishii, K. Izawa, S. Matsumura, K. Wakamura, T. Tanino, T. Tanaka, C. Ogino, H. Fukuda, and A. Kondo, A simple and immediate method for simultaneously evaluating expression level and plasmid maintenance in yeast. J. Biochem. 145, 6 (2009).
8. S. Qin, H. Lin, and P. Jiang, Advances in genetic engineering of marine algae. Biotechnol. Adv. 30, 6 (2012).
9. W. Liu, J. S. Yuan, and C. N. Stewart, Jr, Advanced genetic tools for plant biotechnology. Nat. Rev. Genet. 14 (2013).
10. J. Ishii, T. Kondo, H. Makino, A. Ogura, F. Matsuda, and A. Kondo, Three gene expression vector sets for concurrently expressing multiple genes in Saccharomyces cerevisiae. FEMS Yeast Res. 10 (2014), In press.
11. M. Kuroyanagi, T. Katayama, T. Imai, Y. Yamamoto, S. I. Chisada, Y. Yoshiura, T. Ushijima, T. Matsushita, M. Fujita, A. Nozawa, Y. Suzuki, K. Kikuchi, and H. Okamoto, New approach for fish breeding by chemical mutagenesis: establishment of TILLING method in fugu (Takifugu rubripes) with ENU mutagenesis. BMC Genomics 14, 786 (2013).
12. S. M. Joshi, S. A. Inamdar, J. P. Jadhav, S. P. Govindwar, Random UV mutagenesis approach for enhanced biodegradation of sulfonated azo dye, Green HE4B. Appl. Biochem. Biotechnol. 169, 5 (2013).
13. R. Daly and M. T. Hearn, Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production. J. Mol. Recognit. 18, 2 (2005).
14. S. Togawa, J. Ishii, A. Ishikura, T. Tanaka, C. Ogino, and A. Kondo, Importance of asparagine residues at positions 13 and 26 on the amino-terminal domain of human somatostatin receptor subtype-5 in signaling. J. Biochem. 147, 6 (2010).
15. J. Ishii, K. Yoshimura, T. Hasunuma, and A. Kondo, Reduction of furan derivatives by overexpressing NADH-dependent Adh1 improves ethanol fermentation using xylose as sole carbon source with Saccharomyces cerevisiae harboring XR-XDH pathway. Appl. Microbiol. Biotechnol. 97, 6 (2013).
16. G. Fenalti, P. M. Giguere, V. Katritch, X. P. Huang, A. A. Thompson, V. Cherezov, B. L. Roth, and R. C. Stevens, Molecular control of δ-opioid receptor signaling. Nature 506, 7487 (2014).
17. T. Gaj, C. A. Gersbach, and C. F. Barbas 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 7 (2013).
18. S. J. Gratz, J. Wildonger, M. M. Harrison, and K. M. O'Connor-Giles, CRISPR/Cas9-mediated genome engineering and the promise of designer flies on demand. Fly (Austin) 7, 4 (2013).
19. D. Bikard and L. A. Marraffini, Control of gene expression by CRISPR-Cas systems. F1000Prime Rep. 5, 47 (2013).
20. J. Reeks, J. H. Naismith, and M. F. White, CRISPR interference: A structural perspective. Biochem. J. 453, 2 (2013).
21. A. Kondo, J. Ishii, K. Y. Hara, T. Hasunuma, and F. Matsuda, Development of microbial cell factories for bio-refinery through synthetic bioengineering. J. Biotechnol. 163, 2 (2013).
22. F. Matsuda, J. Ishii, T. Kondo, K. Ida, H. Tezuka, and A. Kondo, Increased isobutanol production in Saccharomyces cerevisiae by eliminating competing pathways and resolving cofactor imbalance. Microb. Cell Fact. 12, 119 (2013).
23. T. Kondo, H. Tezuka, J. Ishii, F. Matsuda, C. Ogino, and A. Kondo, Genetic engineering to enhance the Ehrlich pathway and alter carbon flux for increased isobutanol production from glucose by Saccharomyces cerevisiae. J. Biotechnol. 159, 1 (2012).
24. T. Hasunuma, T. Sanda, R. Yamada, K. Yoshimura, J. Ishii, and A. Kondo, Metabolic pathway engineering based on metabolomics confers acetic and formic acid tolerance to a recombinant xylose-fermenting strain of Saccharomyces cerevisiae. Microb. Cell Fact. 10, 2 (2011).
25. S. Atsumi, A. F. Cann, M. R. Connor, C. R. Shen, K. M. Smith, M. P. Brynildsen, K. J. Chou, T. Hanai, and J. C. Liao, Metabolic engineering of Escherichia coli for 1-butanol production. Metab. Eng. 10, 6 (2008).
26. S. Molloy, J. Nikodinovic-Runic, L. B. Martin, H. Hartmann, F. Solano, H. Decker, and K. E. O'Connor, Engineering of a bacterial tyrosinase for improved catalytic efficiency towards d-tyrosine using random and site directed mutagenesis approaches. Biotechnol. Bioeng. 110, 7 (2013).
27. Y. Dong, J. Yan, H. Du, M. Chen, T. Ma, and L. Feng, Engineering of LadA for enhanced hexadecane oxidation using randomand site-directed mutagenesis. Appl. Microbiol. Biotechnol. 94, 4 (2012).
28. J. Kong, S. R. Kim, K. Binley, I. Pata, K. Doi, J. Mannik, J. Zernant-Rajang, O. Kan, S. Iqball, S. Naylor, J. R. Sparrow, P. Gouras, and R. Allikmets, Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther. 15, 19 (2008).
29. H. W. Park, J. S. Cho, C. K. Park, S. J. Jung, C. H. Park, S. J. Lee, S. B. Oh, Y. S. Park, and M. S. Chang, Directed induction of functional motor neuron-like cells from genetically engineered human mesenchymal stem cells. PLoS One 7, 4 (2012).
30. D. Y. Hwang, D. S. Kim, and D. W. Kim, Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems. J. Cell. Biochem. 109, 2 (2010).
31. S. L. Hampton and A. I. Kinnaird, Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery. Cell Biol. Toxicol. 26, 1 (2010).
32. J. Ishii, N. Yoshimoto, K. Tatematsu, S. Kuroda, C. Ogino, H. Fukuda, and A. Kondo, Cell wall trapping of autocrine peptides for human G-protein-coupled receptors on the yeast cell surface. PLoS One 7, 5 (2012).
33. Y. Nakamura, J. Ishii, and A. Kondo, Rapid, facile detection of heterodimer partners for target human G-protein-coupled receptors using a modified split-ubiquitin membrane yeast two-hybrid system. PLoS One 8, 6 (2013).
34. S. Carroll and M. Al-Rubeai, The selection of high-producing cell lines using flow cytometry and cell sorting. Expert Opin. Biol. Ther. 4, 11 (2004).
35. L. Fan, I. Kadura, L. E. Krebs, J. L. Larson, D. M. Bowden, and C. C. Frye, Development of a highly-efficient CHO cell line generation system with engineered SV40E promoter. J. Biotechnol. 168, 4 (2013).
36. C. Lang, D. Schüler, and D. Faivre, Synthesis of magnetite nanoparticles for bio- and nanotechnology: genetic engineering and biomimetics of bacterial magnetosomes. Macromol. Biosci. 7, 2 (2007).
37. E. Y. Kim and D. Tullman-Ercek, Engineering nanoscale protein compartments for synthetic organelles. Curr. Opin. Biotechnol. 24, 4 (2013).
38. E. Josef, K. Barat, I. Barsht, M. Zilberman, and H. Bianco-Peled, Composite hydrogels as a vehicle for releasing drugs with a wide range of hydrophobicities. Acta Biomater. 9, 11 (2013).
39. A. Tripathi, S. Saravanan, S. Pattnaik, A. Moorthi, N. C. Partridge, and N. Selvamurugan, Bio-composite scaffolds containing chitosan/nano- hydroxyapatite/nano-copper-zinc for bone tissue engineering. Int. J. Biol. Macromol. 50, 1 (2012).
40. D. F. Williams, On the nature of biomaterials. Biomaterials 30, 30 (2009).
41. S. Pedroso and I. A. Guillen, Microarray and nanotechnology applications of functional nanoparticles. Comb. Chem. High Throughput Screen. 9, 5 (2006).
42. R. Singh and J. W. Lillard, Jr, Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86, 3 (2009).
43. Y. Liu, J. Tan, A. Thomas, D. Ou-Yang, and V. R. Muzykantov, The shape of things to come: Importance of design in nanotechnology for drug delivery. Ther. Deliv. 3, 2 (2012).
44. W. Cai, T. Gao, H. Hong, and J. Sun, Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol. Sci. Appl. 1, 11 (2008).
45. I. A. Siddiqui, V. M. Adhami, J. C. Chamcheu, and H. Mukhtar, Impact of nanotechnology in cancer: emphasis on nanochemoprevention. Int. J. Nanomedicine 2012, 7 (2012).
46. M. Tiwari, Nano cancer therapy strategies. J. Cancer Res. Ther. 8, 1 (2012).
47. F. M. Kievit and M. Zhang, Cancer nanotheranostics: Improving imaging and therapy by targeted delivery across biological barriers. Adv. Mater. 23, 36 (2011).
48. S. Y. Madani, N. Naderi, O. Dissanayake, A. Tan, and A. M. Seifalian, A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int. J. Nanomedicine 2011, 6 (2011).
49. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 12 (2010).
50. N. R. Jabir, S. Tabrez, G. M. Ashraf, S. Shakil, G. A. Damanhouri, and M. A. Kamal, Nanotechnology-based approaches in anticancer research. Int. J. Nanomedicine 2012, 7 (2012).
51. D. G. Yu, W. C. Lin, and M. C. Yang, Surface modification of poly(l-lactic acid) membrane via layer-by-layer assembly of silver nanoparticle-embedded polyelectrolyte multilayer. Bioconjug. Chem. 18, 5 (2007).
52. J. Panyam and V. Labhasetwar, Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 3 (2003).
53. K. Kataoka, A. Harada, and Y. Nagasaki, Block copolymer micelles for drug delivery: Design, characterization and biological significance. Adv. Drug Deliv. Rev. 47, 1 (2001).
54. H. Heiati, N. Phillips, and R. Tawashi, Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm. Res. 13, 9 (1996).
55. Y. Y. Yang, Y. Wang, R. Powell, and P. Chan, Polymeric core-shell nanoparticles for therapeutics. Clin. Exp. Pharmacol. Physiol. 33, 5 (2006).
56. T. C. Yih and M. Al-Fandi, Engineered nanoparticles as precise drug delivery systems. J. Cell. Biochem. 97, 6 (2006).
57. S. K. Nitta and K. Numata, Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. Int. J. Mol. Sci. 14, 1 (2013).
58. D. E. Meyer and A. Chilkoti, Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: Examples from the elastin-like polypeptide system. Biomacromolecules 3, 2 (2002).
59. J. Cappello, J. Crissman, M. Dorman, M. Mikolajczak, G. Textor, M. Marquet, and F. Ferrari, Genetic engineering of structural protein polymers. Biotechnol. Prog. 6, 3 (1990).
60. H. S. Creel, M. J. Fournier, T. L. Mason, and D. A. Tirrell, Genetically-directed syntheses of new polymeric materials. Efficient expression of a monodisperse copolypeptide containing fourteen tandemly repeated-(AlaGly)4ProGluGly-elements. Macromolecules 24, 5 (1991).
61. D. T. McPherson, J. Xu, and D. W. Urry, Product purification by reversible phase transition following Escherichia coli expression of genes encoding up to 251 repeats of the elastomeric pentapeptide GVGVP. Protein Expr. Purif. 7, 1 (1996).
62. Y. Fukushima, Genetically engineered syntheses of tandem repetitive polypeptides consisting of glycine-rich sequence of spider dragline silk. Biopolymers, 45, 4 (1998).
63. R. A. McMillan, T. A. T. Lee, and V. P. Conticello, High-resolution topographic imaging of environmentally responsive, elastin-mimetic hydrogels. Macromolecules 32, 26 (1999).
64. G. Sun, P. Y. Hsueh, S. M. Janib, S. Hamm-Alvarez, and J. A. MacKay, Design and cellular internalization of genetically engineered polypeptide nanoparticles displaying adenovirus knob domain. J. Control. Release 155, 2 (2011).
65. D. J. Callahan, W. Liu, X. Li, M. R. Dreher, W. Hassouneh, M. Kim, P. Marszalek, and A. Chilkoti, Triple stimulus-responsive polypeptide nanoparticles that enhance intratumoral spatial distribution. Nano. Lett. 12, 4 (2012).
66. S. R. MacEwan and A. Chilkoti, Digital switching of local arginine density in a genetically encoded self-assembled polypeptide nanoparticle controls cellular uptake. Nano Lett. 12, 6 (2012).
67. J. L. Osborne, R. Farmer, and K. A. Woodhouse, Self-assembled elastin-like polypeptide particles. Acta Biomater. 4 (2008).
68. A. Zeltins, Construction and characterization of virus-like particles: A review. Mol. Biotechnol. 53, 1 (2013).
69. B. Lamarre and M. G. Ryadnov, Self-assembling viral mimetics: One long journey with short steps. Macromol. Biosci. 11, 4 (2011).
70. Y. Seow and M. J. Wood, Biological gene delivery vehicles: Beyond viral vectors. Mol. Ther. 17, 5 (2009).
71. R. A. Lamb and D. Kolakofsky, Paramyxoviridae: The viruses and their replication, Fundamental Virology, 4th edn. (2001).
72. S. Fujita, A. Eguchi, J. Okabe, A. Harada, K. Sasaki, N. Ogiwara, Y. Inoue, T. Ito, H. Matsuda, K. Kataoka, A. Kato, M. Hasegawa, and M. Nakanishi, Sendai virus-mediated gene delivery into hepatocytes via isolated hepatic perfusion. Biol. Pharm. Bull. 29, 8 (2006).
73. M. Nakanishi and M. Otsu, Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. Curr. Gene Ther. 12, 5 (2012).
74. Y. Okada, Sendai virus-induced cell fusion. Methods Enzymol. 221 (1993).
75. K. Yamada, A. Moriguchi, R. Morishita, M. Aoki, Y. Nakamura, H. Mikami, T. Oshima, M. Ninomiya, Y. Kaneda, J. Higaki, and T. Ogihara, Efficient oligonucleotide delivery using the HVJliposome method in the central nervous system. Am. J. Physiol. 271 (1996).
76. K. Hayashi, R. Morishita, H. Nakagami, S. Yoshimura, A. Hara, K. Matsumoto, T. Nakamura, T. Ogihara, Y. Kaneda, and N. Sakai, Gene therapy for preventing neuronal death using hepatocyte growth factor: In vivo gene transfer of HGF to subarachnoid space prevents delayed neuronal death in gerbil hippocampal CA1 neurons. Gene Ther. 8, 15 (2001).
77. Y. Hagihara, Y. Saitoh, Y. Kaneda, E. Kohmura, and T. Yoshimine, Widespread gene transfection into the central nervous system of primates. Gene Ther. 7, 9 (2000).
78. Y. Kaneda, Y. Saeki, and R. Morishita, Gene therapy using HVJliposomes: the best of both worlds?. Mol. Med. Today 5, 7 (1999).
79. Y. Kaneda, T. Nakajima, T. Nishikawa, S. Yamamoto, H. Ikegami, N. Suzuki, H. Nakamura, R. Morishita, and H. Kotani, Hemagglutinating Virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol. Ther. 6, 2 (2002).
80. C. M. Hoff and P. J. Margetts, Adenovirus-based transient expression systems for peritoneal membrane research. Perit. Dial. Int. 26, 5 (2006).
81. A. Srivastava, E. W. Lusby, and K. I. Berns, Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45, 2 (1983).
82. W. W. Hauswirth and K. I. Berns, Origin and termination of adenoassociated virus DNA replication. Virology 78, 2 (1977).
83. E. Lusby, K. H. Fife, and K. I. Berns, Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA. J. Virol. 34, 2 (1980).
84. R. J. Samulski, K. I. Berns, M. Tan, and N. Muzyczka, Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl. Acad. Sci. USA 79, 6 (1982).
85. R. J. Samulski, A. Srivastava, K. I. Berns, and N. Muzyczka, Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell 33, 1 (1983).
86. A. Srivastava, Replication of the adeno-associated virus DNA termini in vitro. Intervirology 27, 3 (1987).
87. C. Giraud, E. Winocour, and K. I. Berns, Recombinant junctions formed by site-specific integration of adeno-associated virus genome into an episome. J. Virol. 69, 11 (1995).
88. X. S. Wang, S. Ponnazhagan, and A. Srivastava, Rescue and replication signals of the adeno-associated virus 2 genome. J. Mol. Biol. 250, 5 (1995).
89. K. I. Berns, and C. Giraud, Biology of adeno-associated virus. Curr. Top. Microbiol. Immunol. 218 (1996).
90. K. I. Berns, R. M. Kotin, and M. A. Labow, Regulation of adenoassociated virus DNA replication. Biochim. Biophys. Acta 951, 2 (1988).
91. N. Muzyczka, Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr. Top. Microbiol. Immunol. 158 (1992).
92. T. R. Flotte, S. A. Afione, and P. L. Zeitlin, Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am. J. Respir. Cell Mol.Biol. 11, 5 (1994).
93. G. Podsakoff, K. K. Wong, Jr, and S. Chatterjee, Stable and efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J. Virol. 68, 9 (1994).
94. V. M. Vogt and M. N. Simon, Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy. J. Virol. 73, 8 (1999).
95. M. I. Bukrinsky, S. Haggerty, M. P. Dempsey, N. Sharova, A. Adzhubel, L. Spitz, P. Lewis, D. Goldfarb, M. Emerman, and M. Stevenson, A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365, 6447 (1993).
96. I. M. Jones and Y. Morikawa, The molecular basis of HIV capsid assembly. Rev. Med. Virol. 8, 2 (1998).
97. D. Escors and K. Breckpot, Lentiviral vectors in gene therapy: their current status and future potential. Arch. Immunol. Ther. Exp. 58, 2 (2010).
98. A. G. Dalgleish, P. C. Beverley, P. R. Clapham, D. H. Crawford, M. F. Greaves, and R. A. Weiss, The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312, 5996 (1984).
99. N. R. Landau, M. Warton, and D. R. Littman, The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4. Nature 334, 6178 (1988).
100. Q. J. Sattentau and J. P. Moore, Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174, 407 (1991).
101. G. Alkhatib, C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger, CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1. Science 272, 5270 (1996).
102. Y. Feng, C. C. Broder, P. E. Kennedy, and E. A. Berger, HIV-1 entry cofactor: Functional cDNA cloning of a seventransmembrane, G protein-coupled receptor. Science 272, 5263 (1996).
103. K. Pluta, M. M. Kacprzak, Use of HIV as a gene transfer vector. Acta Biochim. Pol. 56, 4 (2009).
104. M. D. Miller, C. M. Farnet, F. D. Bushman, Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition. J. Virol. 71, 7 (1997).
105. M. I. Bukrinsky, N. Sharova, M. P. Dempsey, T. L. Stanwick, A. G. Bukrinskaya, S. Haggerty, and M. Stevenson, Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc. Natl. Acad. Sci. USA 89, 14 (1992).
106. G. Romano, P. P. Claudio, T. Tonini, and A. Giordano, Human immunodeficiency virus type 1 (HIV-1) derived vectors: safety considerations and controversy over therapeutic applications. Eur. J. Dermatol. 13, 5 (2003).
107. J. S. Wadia and S. F. Dowdy, Protein transduction technology. Curr. Opin. Biotechnol. 13, 1 (2002).
108. M. Lewin, N. Carlesso, C. H. Tung, X. W. Tang, D. Cory, D. T. Scadden, and R. Weissleder, Tat peptidederivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18, 4 (2000).
109. A. Eguchi, T. Akuta, H. Okuyama, T. Senda, H. Yokoi, H. Inokuchi, S. Fujita, T. Hayakawa, K. Takeda, M. Hasegawa, and M. Nakanishi, Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. 276, 28 (2001).
110. E. Vives, P. Brodin, and B. Lebleu, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 25 (1997).
111. F. Duchardt, M. Fotin-Mleczek, H. Schwarz, R. Fischer, and R. Brock, A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 7 (2007).
112. I. Nakase, A. Tadokoro, N. Kawabata, T. Takeuchi, H. Katoh, K. Hiramoto, M. Negishi, M. Nomizu, Y. Sugiura, and S. Futaki, Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 46, 2 (2007).
113. S. Console, C. Marty, C. Garcia-Echeverria, R. Schwendener, and K. Ballmer-Hofer, Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278, 37 (2003).
114. G. M. Poon and J. Gariepy, Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. Biochem. Soc. Trans. 35, 4 (2007).
115. S. Futaki, I. Nakase, A. Tadokoro, T. Takeuchi, and A. T. Jones, Arginine-rich peptides and their internalization mechanisms. Biochem. Soc. Trans. 35, 4 (2007).
116. S. Al-Taei, N. A. Penning, J. C. Simpson, S. Futaki, T. Takeuchi, I. Nakase, and A. T. Jones, Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. Bioconjugate Chem. 17, 1 (2006).
117. M. M. Fretz, N. A. Penning, S. Al-Taei, S. Futaki, T. Takeuchi, I. Nakase, G. Storm, and A. T. Jones, Temperature-, concentration- and cholesterol-dependent translocation of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem. J. 403, 2 (2007).
118. N. Yokoyama, M. A. Kawano, H. Tsukamoto, T. Enomoto, T. Inoue, R. U. Takahashi, A. Nakanishi, T. Imai, T. Wada, and H. Handa, Mutational analysis of the carboxyl-terminal region of the SV40 major capsid protein VP1. J. Biochem. 141, 2 (2007).
119. R. C. Liddington, Y. Yan, J. Moulai, R. Sahli, T. L. Benjamin, and S. C. Harrison, Structure of simian virus 40 at 3.8-A resolution. Nature 354, 6351 (1991).
120. T. Stehle, S. J. Gamblin, Y. Yan, and S. C. Harrison, The structure of simian virus 40 refined at 3.1A resolution. Structure 4, 2 (1996).
121. K. I. Ishizu, H. Watanabe, S. I. Han, S. N. Kanesashi, M. Hoque, H. Yajima, K. Kataoka, and H. Handa, Roles of disulfide linkage and calcium ion-mediated interactions in assembly and disassembly of virus-like particles composed of simian virus 40 VP1 capsid protein. J. Virol. 75, 1 (2001).
122. Z. Sandalon, N. Dalyot-Herman, A. B. Oppenheim, and A. Oppenheim, In vitro assembly of SV40 virions and pseudovirions: Vector development for gene therapy. Hum. Gene Ther. 8, 7 (1997).
123. D. Chang, C. Y. Fung, W. C. Ou, P. C. Chao, S. Y. Li, M. Wang, Y. L. Huang, T. Y. Tzeng, and R. T. Tsai, Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells. J. Gen. Virol. 78, 6 (1997).
124. W. C. Ou, M. Wang, C. Y. Fung, R. T. Tsai, P. C. Chao, T. H. Hseu, and D. Chang, The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells. J. Gen. Virol. 80, 1 (1999).
125. T. C. Li, N. Takeda, K. Kato, J. Nilsson, L. Xing, L. Haag, R. H. Cheng, and T. Miyamura, Characterization of self-assembled virus-like particles of human polyomavirus BK generated by recombinant baculoviruses. Virology 311, 1 (2003).
126. A. Touze, L. Bousarghin, C. Ster, A. L. Combita, P. Roingeard, and P. Coursaget, Gene transfer using human polyomavirus BK virus-like particles expressed in insect cells. J. Gen. Virol. 82, 12 (2001).
127. J. Forstova, N. Krauzewicz, S. Wallace, A. J. Street, S. M. Dilworth, S. Beard, and B. E. Griffin, Cooperation of structural proteins during late events in the life cycle of polyomavirus. J. Virol. 67, 3 (1993).
128. L. Montross, S. Watkins, R. B. Moreland, H. Mamon, D. L. Caspar, and R. L. Garcea, Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1. J. Virol. 65, 9 (1991).
129. B. Wrobel, Y. Yosef, A. B. Oppenheim, and A. Oppenheim, Production and purification of SV40 major capsid protein (VP1) in Escherichia coli strains deficient for the GroELS chaperone machine. J. Biotechnol. 84, 3 (2000).
130. K. V. Shah and D. E. Rollison, Investigation of the SV40-human cancer association:look for the full signature of the virus. Dis. Markers 17, 3 (2001).
131. C. Kimchi-sarfaty, O. Ben-Nun-Shaul, D. Rund, A. Oppenheim, and M. M. Gottesman, In Vitro-Packaged SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer. Hum. Gene Ther. 13, 2 (2002).
132. C. Kimchi-Sarfaty, M. Arora, Z. Sandalon, A. Oppenheim, and M. M. Gottesman, High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum. Gene Ther. 14, 2 (2003).
133. C. Kimchi-Sarfaty and M. M. Gottesman, SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr. Pharm. Biotechnol. 5, 5 (2004).
134. P. Tiollais, C. Pourcel, and A. Dejean, The hepatitis B virus. Nature 317, 6037 (1985).
135. K. H. Heermann, U. Goldmann, W. Schwartz, T. Seyffarth, H. Baumgarten, and W. H. Gerlich, Large surface proteins of hepatitis B virus containing the pre-S sequence. J. Virol. 52, 2 (1984).
136. A. R. Neurath and S. B. Kent, The pre-S region of hepadnavirus envelope proteins. Adv. Virus Res. 34 (1988).
137. A. R. Neurath, S. B. Kent, N. Stick, and K. Parker, Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46, 3 (1986).
138. P. Pontisso, M. G. Ruvoletto, W. H. Gerlich, K. H. Heermann, R. Bardini, and A. Alberti, Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. Virology 173, 2 (1989).
139. S. De Meyer, Z. J. Gong, W. Suwandhi, J. Van Pelt, A. Soumillion, and S. H. Yap, Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes. J. Viral Hepat. 4, 3 (1997).
140. S. Kuroda, S. Otaka, T. Miyazaki, M. Nakao, and Y. Fujisawa, Hepatitis B virus envelope L protein particles. Synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. J. Biol. Chem. 267, 3 (1992).
141. T. Yamada, H. Iwabuki, T. Kannno, H. Tanaka, T. Kawai, H. Fukuda, A. Kondo, M. Seno, K. Tanizawa, and S. Kuroda, Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. Vaccine 19, 23 (2001).
142. J. Jung, T. Matsuzaki, K. Tatematsu, T. Okajima, K. Tanizawa, and S. Kuroda, Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J. Control Release 126, 3 (2008).
143. A. Cooper and Y. Shaul, Recombinant viral capsids as an efficient vehicle of oligonucleotide delivery into cells. Biochem. Biophys. Res. Commun. 327, 4 (2005).
144. K. W. Leea and W. S. Tana, Recombinant hepatitis B virus core particles: Association, dissociation and encapsidation of green fluorescent protein. J. Virol. Meth. 151, 2 (2008).
145. H. Wizemann and A. von Brunn, Purification of E. coli-expressed HIS-tagged hepatitis B core antigen by Ni2+-chelate affinity chromatography. J. Virol. Meth. 77, 2 (1999).
146. A. Cooper and Y. Shaul1, Clathrin-mediated endocytosis and lysosomal cleavage of Hepatitis B virus capsid-like core particles. J. Biol. Chem. 281, 24 (2006).
147. S. Ramishetti and L. Huang, Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther. Deliv. 3, 12 (2012).
148. S. E. Gratton, P. A. Ropp, P. D. Pohlhaus, J. C. Luft, V. J. Madden, M. E. Napier, and J. M. DeSimone, The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA 105, 33 (2008).
149. P. Decuzzi, R. Pasqualini, W. Arap, and M. Ferrari, Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 26, 1 (2009).
150. J. A. Champion and S. Mitragotri, Shape induced inhibition of phagocytosis of polymer particles. Pharm. Res. 26, 1 (2009).
151. B. R. Smith, P. Kempen, D. Bouley, A. Xu, Z. Liu, N. Melosh, H. Dai, R. Sinclair, and S. S. Gambhir, Shape matters: Intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Letts. 12, 7 (2012).
152. M. E. Davis, Z. G. Chen, and D. M. Shin, Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 9 (2008).
153. F. Alexis, E. Pridgen, L. K. Molnar, and O. C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 4 (2008).
154. M. Longmire, P. L. Choyke, and H. Kobayashi, Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats. Nanomedicine (Lond.) 3, 5 (2008).
155. A. L. Klibanov, K. Maruyama, V. P. Torchilin, and L. Huang, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 1 (1990).
156. J. A. Barreto, W. O'Malley, M. Kubeil, B. Graham, H. Stephan, and L. Spiccia, Nanomaterials: Applications in cancer imaging and therapy. Adv. Mater. 23, 12 (2011).
157. Y. G. Kuznetsov, A. J. Malkin, R. W. Lucas, M. Plomp, and A. McPherson, Imaging of viruses by atomic force microscopy. J. Gen. Virol. 82, 9 (2001).
158. M. G. Rossmann, V. V. Mesyanzhinov, F. Arisaka, and P. G. Leiman, The bacteriophage T4 DNA injection machine. Curr. Opin. Struct. Biol. 14, 2 (2004).
159. M. L. Schipper, G. Iyer, A. L. Koh, Z. Cheng, Y. Ebenstein, A. Aharoni, S. Keren, L. A. Bentolila, J. Li, J. Rao, X. Chen, U. Banin, A. M. Wu, R. Sinclair, S. Weiss, and S. S. Gambhir, Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small 5, 1 (2009).
160. Y. Geng, P. Dalhaimer, S. Cai, R. Tsai, M. Tewari, T. Minko, and D. E. Discher, Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2, 4 (2007).
161. R. L. Juliano and D. Stamp, The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem. Biophys. Res. Commun. 63, 3 (1975).
162. P. Aggarwal, J. B. Hall, C. B. Mcleland, M. A. Dobrovolskaia, and S. E. Mcneil, Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61, 6 (2009).
163. T. M. Allen and C. Hansen, Pharmacokinetics of stealth versus conventional liposomes: Effect of dose. Biochim. Biophys. Acta 1068, 2 (1991).
164. Y. Malam, M. Loizidou, and A. M. Seifalian, Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30, 11 (2009).
165. C. Gonçalves, E. Torrado, T. Martins, P. Pereira, J. Pedrosa, and M. Gama, Dextrin nanoparticles: Studies on the interaction with murine macrophages and blood clearance. Colloids Surf. B Biointerfaces 75, 2 (2010).
166. Y. Sheng, Y. Yuan, C. Liu, X. Tao, X. Shan, and F. Xu, In vitro macrophage uptake and in vivo biodistribution of PLA-PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content. J. Mater Sci. Mater Med. 20, 9 (2009).
167. J. W. Dear, H. Kobayashi, S. K. Jo, M. K. Holly, X. Hu, P. S. Yuen, M. W. Brechbiel, and R. A. Star, Dendrimerenhanced MRI as a diagnostic and prognostic biomarker of sepsis-induced acute renal failure in aged mice. Kidney Int. 67, 6 (2005).
168. T. Nakamura, H. Akita, Y. Yamada, H. Hatakeyama, and H. Harashima, A multifunctional envelope-type nanodevice for use in nanomedicine: Concept and applications. Acc. Chem. Res. 45, 7 (2012).
169. T. Wang, J. R. Upponi, and V. P. Torchilin, Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int. J. Cancer. 427, 1 (2012).
170. B. Romberg, W. E. Hennink, and G. Storm, Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25, 1 (2008).
171. H. Hatakeyama, H. Akita, K. Kogure, and H. Harashima, Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 14, 1 (2007).
172. L. S. Jabr-Milane, L. E. van Vlerken, S. Yadav, and M. M. Amiji. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 34, 7 (2008).
173. R. Sinha, G. J. Kim, S. Nie, and D. M. Shin, Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 5, 8 (2006).
174. J. Fang, H. Nakamura, and H. Maeda. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 3 (2011).
175. F. Yuan, M. Leunig, S. K. Huang, D. A. Berk, D. Papahadjopoulos, and R. K. Jain, Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54, 13 (1994).
176. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 12 (2007).
177. T. M. Allen and P. R. Cullis, Drug delivery systems: entering the mainstream. Science 303, 5665 (2004).
178. S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 95, 8 (1998).
179. C. H. Heldin, K. Rubin, K. Pietras, and A. Ostman, High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 4, 10 (2004).
180. R. E. Serda, B. Godin, E. Blanco, C. Chiappini, and M. Ferrari, Multi-stage delivery nano-particle systems for therapeutic applications. Biochim. Biophys. Acta 1810, 3 (2011).
181. D. B. Kirpotin, D. C. Drummond, Y. Shao, M. R. Shalaby, K. Hong, U. B. Nielsen, J. D. Marks, C. C. Benz, and J. W. Park, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 13 (2006).
182. K. Saga, K. Tamai, M. Kawachi, T. Shimbo, H. Fujita, T. Yamazaki, and Y. Kaneda, Functional modification of Sendai virus by siRNA. J. Biotechnol. 133, 3 (2008).
183. T. Shimbo, M. Kawachi, K. Saga, H. Fujita, T. Yamazaki, K. Tamai, and Y. Kaneda, Development of a transferrin receptor-targeting HVJ-E vector. Biochem. Biophys. Res. Commun. 364, 3 (2007).
184. L. Naldini, U. Blomer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono, In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 5259 (1996).
185. S. Froelich, L. Ziegler, K. Stroup, and P. Wang, Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule. Biotechnol. Bioeng. 104, 1 (2009).
186. L. Yang, L. Bailey, D. Baltimore, and P. Wang, Targeting lentiviral vectors to specific cell types in vivo. Proc. Natl. Acad. Sci. USA 103, 31 (2006).
187. H. Yang, K. I. Joo, L. Ziegler, and P. Wang, Cell type-specific targeting with surface-engineered lentiviral vectors codisplaying OKT3 antibody and fusogenic molecule. Pharm. Res. 26, 6 (2009).
188. R. U. Takahashi, S. N. Kanesashi, T. Inoue, T. Enomoto, M. A. Kawano, H. Tsukamoto, F. Takeshita, T. Imai, T. Ochiya, K. Kataoka, Y. Yamaguchi, and H. Handa, Presentation of functional foreign peptides on the surface of SV40 virus-like particles. J. Biotechnol. 135, 4 (2008).
189. E. Ruoslahti and M. D. Pierschbacher, Newperspectives in cell adhesion: RGD and integrins. Science 238, 4826 (1987).
190. D. Beckett, E. Kovaleva, and P. J. Schatz, A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. 8, 4 (1999).
191. A. Chapman-Smith and J. E. Cronan, Jr, Molecular biology of biotin attachment to proteins. J. Nutr. 129, 2 (1999).
192. T. Shishido, Y. Azumi, T. Nakanishi, M. Umetsu, T. Tanaka, C. Ogino, H. Fukuda, and A. Kondo, Biotinylated bionanocapsules for displaying diverse ligands toward cell-specific delivery. J. Biochem. 146, 6 (2009).
193. S. Futaki, T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, K. Ueda, and Y. Sugiura, Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276, 8 (2001).
194. E. Vivès, P. Brodin, and B. Lebleu, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 25 (1997).
195. D. Derossi, A. H. Joliot, G. Chassaing, and A. Prochiantz, The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269, 14 (1994).
196. T. Shishido, D. Yonezawa, K. Iwata, T. Tanaka, C. Ogino, H. Fukuda, and A. Kondo, Construction of arginine-rich peptide displaying bionanocapsules. Bioorg. Med. Chem. Lett. 19, 5 (2009).
197. L. Jendeberg, B. Persson, R. Anderssonm, R. Karlsson, M. Uhlén, and B. Nilsson, Kinetic analysis of the interaction between protein A domain variants and human Fc plasmon resonance detection. J. Mol. Recognit. 8, 4 (1995).
198. B. Nilsson, T. Moks, B. Jansson, L. Abrahmsén, A. Elmblad, E. Holmgren, C. Henrichson, T. A. Jones, and M. Uhlén, A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1, 2 (1987).
199. Y. Tsutsui, K. Tomizawa, M. Nagita, H. Michiue, T. Nishiki, I. Ohmori, M. Seno, and H. Matsui, Development of bionanocapsules targeting brain tumors. J. Control. Release 122, 2 (2007).
200. N. Kurata, T. Shishido, M. Muraoka, T. Tanaka, C. Ogino, H. Fukuda, and A. Kondo, Specific protein delivery to target cells by antibody-displaying bionanocapsules. J. Biochem. 144, 6 (2008).
201. P. A. Nygren, Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 275, 11 (2008).
202. A. Orlova, V. Tolmachev, R. Pehrson, M. Lindborg, T. Tran, M. Sandström, F. Y. Nilsson, A. Wennborg, L. Abrahmsén, and J. Feldwisch, Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res. 67, 5 (2007).
203. T. Shishido, H. Mieda, S. Y. Hwang, Y. Nishimura, T. Tanaka, C. Ogino, H. Fukuda, and A. Kondo, Affibody-displaying bionanocapsules for specific drug delivery to HER2-expressing cancer cells. Bioorg. Med. Chem. Lett. 20, 19 (2010).
204. F. Birnbaum and M. Nassal, Hepatitis B virus nucleocapsid assembly: Primary structure requirements in the core protein. J. Virol. 64, 7 (1990).
205. P. A. Kratz, B. Bottcher, and M. Nassal, Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl. Acad. Sci. USA 96, 5 (1999).
206. Y. Nishimura, W. Mimura, I. F. Mohamed Suffian, T. Amino, J. Ishii, C. Ogino, and A. Kondo, Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule. J. Biochem. 153, 3 (2013).
207. A. Mahapatro and D. K. Singh, Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J. Nanobiotechnology 9, 55 (2011).
208. Q. He and J. Shi, Mesoporous silica nanoparticle based nano drug delivery systems: Synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J. Mat. Chem. 21, 16 (2011).
209. F. Torney, B. G. Trewyn, V. Lin, and K. Wang, Mesoporous silica nanoparticles deliver DNA and chemicals into plants. Nat. Nano 2, 5 (2007).
210. H. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J. I. Zink, and A. E. Nel, Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4, 8 (2010).
211. T. R. Flotte and B. J. Carter, Adeno-associated virus vectors for gene therapy. Gene Ther. 2, 6 (1995).
212. E. Shaughnessy, D. Lu, S. Chatterjee, and K. K. Wong, Jr, Parvoviral vectors for the gene therapy of cancer. Semin. Oncol. 23, 1 (1996).
213. P. J. Quesenberry, G. S. Stein, B. G. Forget, and S. M. Weissman, Delivery system for gene therapy: adeno-associated virus 2. Stem Cell Biology and Gene Therapy (2002).
214. R. J. Samulski, L. S. Chang, and T. Shenk, A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 61, 10 (1987).
215. R. J. Samulski, L. S. Chang, and T. Shenk, Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J. Virol. 63, 9 (1989).
216. C. Zheng, A. Voutetakis, B. Goldstein, S. Afione, V. M. Rivera, T. Clackson, M. L. Wenk, M. Boyle, A. Nyska, J. A. Chiorini, M. Vallant, R. D. Irwin, and B. J. Baum, Assessment of the safety and biodistribution of a regulated AAV2 gene transfer vector after delivery to murine submandibular glands. Toxicol. Sci. 123, 1 (2011).
217. M. Malecki, R. Proczka, J. Chorostowska-Wynimko, P. Swoboda, A. Delbani, and J. Pachecka, Recombinant adeno-associated viruses (rAAV2) facilitate the intraperitoneal gene delivery to cancer cells. Oncol. Lett. 1, 1 (2010).
218. T. Inoue, M. A. Kawano, R. U. Takahashi, H. Tsukamoto, T. Enomoto, T. Imai, K. Kataoka, and H. Handa, Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3. J. Biotechnol. 134, 1 (2008).
219. J. F. Conway, N. Cheng, A. Zlotnick, S. J. Stahl, P. T. Wingfield, D. M. Belnap, U. Kanngiesser, M. Noah, and A. C. Steven AC. Hepatitis B virus capsid: Localization of the putative immunodominant loop (residues 78 to 83) on the capsid surface, and implications for the distinction between c and e-antigens. J. Mol. Biol. 279, 5 (1998).
220. C. Beterams, B. Böttcher, and M. Nassal, Packaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsids. FEBS Lett. 481, 2 (2000).
221. J. Kunisawa, T. Masuda, K. Katayama, T. Yoshikawa, Y. Tsutsumi, M. Akashi, T. Mayumi, and S. Nakagawa, Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J. Control. Release 105, 3 (2005).
222. Y. Kaneda, T. Uchida, J. Kim, M. Ishiura, and Y. Okada, The improved efficient method for introducing macromolecules into cells using HVJ (Sendai virus) liposomes with gangliosides. Exp. Cell Res. 173, 1 (1987).
223. K. Kato, M. Nakanishi, Y. Kaneda, T. Uchida, and Y. Okada, Expression of hepatitis B virus surface antigen in adult rat liver. Co-introduction of DNA and nuclear protein by a simplified liposome method. J. Biol. Chem. 266, 6 (1991).
224. K. Apostolov and J. D. Almeida, Interaction of Sendai (HVJ) virus with human erythrocytes: a morphological study of haemolysis cell fusion. J. Gen. Virol. 15, 3 (1972).
225. T. Kasuya, J. Jung, R. Kinoshita, Y. Goh, T. Matsuzaki, M. Iijima, N. Yoshimoto, K. Tanizawa, and S. Kuroda, Chapter 8-Bio-nanocapsule-liposome conjugates for in vivo pinpoint drug and gene delivery. Methods Enzymol. 464 (2009).
226. Y. Zhu, J. Shi, W. Shen, X. Dong, J. Feng, M. Ruan, and Y. Li, Stimuli-responsive controlled drug release from a hollow mesoporous silica sphere/polyelectrolyte multilayer core-shell structure. Angew. Chem. Int. Ed. Engl. 44, 32 (2005).
227. C. R. Thomas, D. P. Ferris, J. H. Lee, E. Choi, M. H. Cho, E. S. Kim, J. F. Stoddart, J. S. Shin, J. Cheon, and J. I. Zink, Noninvasive remote-controlled release of drug molecules in vitro using magnetic actuation of mechanized nanoparticles. J. Am. Chem. Soc. 132, 31 (2010).
228. N. K. Mal, M. Fujiwara, and Y. Tanaka, Photocontrolled reversible release of guest molecules from coumarin-modified mesoporous silica. Nature 421, 6921 (2003).
229. J. D. Lear and W. F. DeGrado, Membrane binding and conformational properties of peptides representing the NH2 terminus of influenza HA-2. J. Biol. Chem. 262, 14 (1987).
230. E. Goormaghtigh, J. De Meutter, F. Szoka, V. Cabiaux, R. A. Parente, and J. M. Ruysschaert, Secondary structure and orientation of the amphipathic peptide GALA in lipid structures. An infrared-spectroscopic approach. Eur. J. Biochem. 195, 2 (1991).
231. S. Futaki, Y. Masui, I. Nakase, Y. Sugiura, T. Nakamura, K. Kogure, and H. Harashima, Unique features of a pH-sensitive fusogenic peptide that improves the transfection efficiency of cationic liposomes. J. Gene. Med. 7, 11 (2005).
232. Y. Nishimura, J. Ishii, F. Okazaki, C. Ogino, and A. Kondo, Complex carriers of affibody-displaying bio-nanocapsules and composition-varied liposomes for HER2-expressing breast cancer cell-specific protein delivery. J. Drug Target. 20, 10 (2012).
233. Y. Nishimura, H. Mieda, J. Ishii, C. Ogino, T. Fujiwara, and A. Kondo, Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bionanocapsules and liposomes. J. Nanobiotechnol. 11, 19 (2013).
234. M. F. Shamji, L. Whitlatch, A. H. Friedman, W. J. Richardson, A. Chilkoti, and L. A. Setton, An injectable and in situ-gelling biopolymer for sustained drug release following perineural administration. Spine 33, 7 (2008).
235. K. P. Greenberg, S. F. Geller, D. V. Schaffer, and J. G. Flannery, Targeted transgene expression in muller glia of normal and diseased retinas using lentiviral vectors. Invest. Ophthalmol. Vis. Sci. 48, 4 (2007).
236. L. Dykman and N. Khlebtsov, Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem. Soc. Rev. 41, 6 (2012).
237. K. Saha, S. S. Agasti, C. Kim, X. Li, and V. M. Rotello, Gold nanoparticles in chemical and biological sensing. Chem. Rev. 112, 5 (2012).
238. X. Wu, T. Ming, X. Wang, P. Wang, J. Wang, and J. Chen, High-photoluminescence-yield gold nanocubes: For cell imaging and photothermal therapy. ACS Nano 4, 1 (2010).
239. K. W. Hu, T. M. Liu, K. Y. Chung, K. S. Huang, C. T. Hsieh, and C. K. Sun, Efficient near-IR hyperthermia and intense nonlinear optical imaging contrast on the gold nanorod-in-shell nanostructures. J. Am. Chem. Soc. 131, 40 (2009).
240. P. Huang, L. Bao, C. Zhang, J. Lin, T. Luo, and D. Yang, Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photothermal therapy. Biomaterials, 32, 36 (2011).
241. D. N. Heo, D. H. Yang, H. J. Moon, J. B. Lee, M. S. Bae, and S. C. Lee, Gold nanoparticles surface-functionalized with paclitaxel drug and biotin receptor as theranostic agents for cancer therapy. Biomaterials 33, 3 (2012).
242. M. W. Ambrogio, C. R. Thomas, Y. L. Zhao, J. I. Zink, and J. F. Stoddart, Mechanized silica nanoparticles: A new frontier in theranostic nanomedicine. Acc. Chem. Res. 44, 10 (2011).
243. I. H. Lee, S. An, M. K. Yu, H. K. Kwon, S. H. Im, and S. Jon, Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J. Control. Release 155, 3 (2011).
244. J. Kim, H. S. Kim, N. Lee, T. Kim, H. Kim, and T. Yu, Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell formagnetic resonance and fluorescence imaging and for drug delivery. Angew. Chem. Int. Ed. Engl. 47, 44 (2008).
245. A. Fujishima and K. Honda, Electrochemical photolysis of water at a semiconductor electrode. Nature 238, 5358 (1972).
246. R. Cai, Y. Kubota, T. Shuin, H. Sakai, K. Hashimoto, and A. Fujishima, Induction of cytotoxicity by photoexcited TiO2 particles. Cancer Res. 52, 8 (1992).
247. Y. Kubota, T. Shuin, C. Kawasaki, M. Hosaka, H. Kitamura, R. Cai, H. Sakai, K. Hashimoto, and A. Fujishima, Photokilling of T-24 human bladder cancer cells with titanium dioxide. Br. J. Cancer 70, 6 (1994).
248. N. Shimizu, C. Ogino, M. F. Dadjour, and T. Murata, Sonocatalytic degradation of methylene blue with TiO2 pellets in water. Ultrason. Sonochem. 14, 2 (2007).
249. C. Ogino, M. F. Dadjour, Y. Iida, and N. Shimizu, Decolorization of methylene blue in aqueous suspensions of titanium peroxide. J. Hazard. Mater. 153, 1 (2008).
250. C. Ogino, N. Shibata, R. Sasai, K. Takaki, Y. Miyachi, S. Kuroda, K. Ninomiya, and N. Shimizu, Construction of protein-modified TiO2 nanoparticles for use with ultrasound irradiation in a novel cell injuring method. Bioorg. Med. Chem. Lett. 20, 17 (2010).
251. K. Ninomiya, C. Ogino, S. Oshima, S. Sonoke, S. Kuroda, and N. Shimizu, Targeted sonodynamic therapy using protein-modified TiO2 nanoparticles. Ultrason. Sonochem. 19, 3 (2012).
252. K. Ninomiya, K. Noda, C. Ogino, S. Kuroda, and N. Shimizu, Enhanced OH radical generation by dual-frequency ultrasound with TiO2 nanoparticles: its application to targeted sonodynamic therapy. Ultrason. Sonochem. 21, 1 (2014).
253. K. Kanehira, T. Banzai, C. Ogino, N. Shimizu, Y. Kubota, and S. Sonezaki, Properties of TiO2-polyacrylic acid dispersions with potential for molecular recognition. Colloids Surf. B Biointerfaces 64, 1 (2008).
254. C. Ogino, K. Kanehira, R. Sasai, S. Sonezaki, and N. Shimizu, Recognition and effective degradation of 17β-estradiol by antibody immobilized TiO2 nanoparticle. J. Bioeng. Biosci. 104, 4 (2007).
255. K. Matsui, M. Karasaki, M. Segawa, S. Y. Hwang, T. Tanaka, C. Ogino, and A. Kondo, Biofunctional TiO2 nanoparticle mediated photokilling of cancer cells using UV irradiation. Med. Chem. Commun. 209, 1 (2010).
256. M. M. Yallapu, S. F. Othman, E. T. Curtis, B. K. Gupta, M. Jaggi, and S. C. Chauhan, Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials 32, 7 (2011).
257. H. Oliveira, E. Perez-Andres, J. Thevenot, O. Sandre, E. Berra, and S. Lecommandoux, Magnetic field triggered drug release from polymersomes for cancer therapeutics. J. Control. Release 169, 3 (2013).
258. M. Shimamura, R. Morishita, M. Endoh, K. Oshima, M. Aoki, S. Waguri, Y. Uchiyama, and Y. Kaneda, HVJ-envelope vector for gene transfer into central nervous system. Biochem. Biophys. Res. Commun. 300, 2 (2003).
259. O. C. Farokhzad and R. Langer, Impact of nanotechnology on drug delivery. ACS Nano 3, 1 (2009).
260. V. Dudu, V. Rotari, and M. J. Vazquez, Sendai virus-based liposomes enable targeted cytosolic delivery of nanoparticles in brain tumor-derived cells. J. Nanobiotechnology 10, 9 (2012).
261. Y. Nishimura, K. Takeda, R. Ezawa, J. Ishii, C. Ogino, and A. Kondo, A Display of pH-sensitive fusogenic GALA peptide facilitates endosomal escape from a bio-nanocapsule via an endocytic uptake pathway. J. Nanobiotechnology (2014).